erlotinib has been researched along with pha 665752 in 3 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (pha 665752) | Trials (pha 665752) | Recent Studies (post-2010) (pha 665752) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 12 | 0 | 8 |
| Protein | Taxonomy | erlotinib (IC50) | pha 665752 (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 1.4 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 3.8 | |
| Hepatocyte growth factor receptor | Homo sapiens (human) | 0.0187 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 3 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 6 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.5315 | |
| Macrophage-stimulating protein receptor | Homo sapiens (human) | 0.068 | |
| Homeodomain-interacting protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 4 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 3 | Homo sapiens (human) | 0.1 | |
| calcium-dependent protein kinase 4 | Plasmodium falciparum 3D7 | 0.021 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Chen, H; Chomchopbun, K; Go, ML; Huynh, TH; Kon, OL; Ng, WH; Yang, T | 1 |
3 other study(ies) available for erlotinib and pha 665752
| Article | Year |
|---|---|
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Protein Kinase Inhibitors | 2007 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Mitochondrial-Targeting MET Kinase Inhibitor Kills Erlotinib-Resistant Lung Cancer Cells.
Topics: | 2016 |